Maravai Lifesciences Holdings (MRVI) EBITDA Margin (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly EBITDA Margin of 3.28% for Q1 2026, up 10166.0% year-over-year from N/an in Q1 2025, and up 97.22% quarter-over-quarter from 117.91% in Q4 2025.
Powered by 
Analysis
Maravai Lifesciences Holdings (MRVI) EBITDA Margin (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' EBITDA Margin history runs 7 years deep, the most recent figure standing at 3.28% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 10166.0% year-over-year to 3.28%; the TTM figure through Mar 2026 stood at 82.19% (up 2776.0% YoY), while the FY2025 annual figure was 115.89%, down 2499.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 3.28%, up from 117.91% in the prior quarter.
- The five-year high for EBITDA Margin was 74.44% in Q2 2022, with the low at 239.93% in Q3 2024.
- The 5-year median for EBITDA Margin is 19.36% (2024), against an average of 35.81%.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin plunged 21688 bps in 2024, then jumped 14137 bps in 2025.
- Maravai Lifesciences Holdings' EBITDA Margin stood at 53.37% in 2022, then sank by 118 bps to 9.64% in 2023, then plunged by 591 bps to 66.66% in 2024, then plunged by 77 bps to 117.91% in 2025, then jumped by 97 bps to 3.28% in 2026.
- Business Quant data shows MRVI's EBITDA Margin at 3.28% in Q1 2026, 117.91% in Q4 2025, and 98.56% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Maravai Lifesciences Holdings | 1.09 Bn | 1.02 Bn | 20.65 Mn | -29.33% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -29.33% |
| Mar 31, 2026 | -3.28% |
| Dec 31, 2025 | -117.91% |
| Sep 30, 2025 | -98.56% |
| Jun 30, 2025 | -139.84% |
| Mar 31, 2025 | -104.93% |
| Dec 31, 2024 | -66.66% |
| Sep 30, 2024 | -239.93% |
| Jun 30, 2024 | -19.36% |
| Mar 31, 2024 | -29.39% |
| Dec 31, 2023 | -9.64% |
| Sep 30, 2023 | -23.06% |
| Jun 30, 2023 | -16.85% |
| Mar 31, 2023 | 3.21% |
| Dec 31, 2022 | 53.37% |
| Sep 30, 2022 | 61.12% |
| Jun 30, 2022 | 74.44% |
| Mar 31, 2022 | 68.51% |
| Dec 31, 2021 | 67.65% |
| Sep 30, 2021 | 75.87% |